2:59 PM
 | 
Dec 02, 2016
 |  BioCentury  |  Finance

Bug-brain axis

Why Axial is targeting the gut microbiome to treat CNS disorders

Investors supplied Axial Biotherapeutics Inc. with enough cash to get human proof of concept showing that correcting microbiome imbalances can treat pathologies and symptoms of neurological disorders.

The newco debuted Nov. 30 with a $19.2 million series A co-led by Longwood Fund and Domain Associates and joined by Kairos Ventures, Heritage Medical Systems and high net worth individuals.

Jim Blair said Domain has been interested in the microbiome for some time and saw Axial’s platform as a unique treatment strategy in neurology.

“If we want to go into...

Read the full 425 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >